Aug 15 (Reuters) - In the latest setback for Pfizer's (PFE.N), opens new tab sickle cell anemia treatments, experimental drug inclacumab failed to meet the main goal in a late-stage trial for patients ...

Inclacumab fails to reduce VOC rates in sickle cell patients in Phase 3 trial. Pfizer will continue developing its broader sickle cell portfolio. See the trading strategy with a perfect track record ...

Pfizer's second-quarter results were better than expected. The drugmaker will still face some near-term uncertainty. However, its long-term prospects look attractive, especially at current levels.

Though the FDA narrowed criteria for the shots, many people still want them, to avoid illness and protect vulnerable family ...

CHICAGO, Aug 25 (Reuters) - Pfizer has urged a Florida federal judge to dismiss lawsuits claiming its birth control shot Depo-Provera can cause users to develop a type of brain tumor, saying ...

Six years ago, Raphaella Kathryn Crosby could barely get out of bed. Then, one change had her dancing around her living room.